, /PRNewswire/ - Willow Biosciences Inc. (" " or the " ") (TSX: WLLW) (OTCQB: ), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces a corporate update on its operations. "The second quarter of 2024 has been the most active quarter to date for Willow's product portfolio," said Dr.
, Willow's President & CEO. "In addition to signing an agreement with global manufacturing giant, Laurus Labs, that added seven new programs in late May, Willow has added a new "proof of concept" agreement with an innovative biotech company in the high growth biopesticide sector," continued Dr. Savile.
On , the Company announced a strategic partnership with Laurus Labs to develop new biobased routes for seven active pharmaceutical ingredients. Willow will leverage its AI-driven technology platform and extensive experience in enzyme, strain, and process engineering to deliver biobased processes for high-value Active Pharmaceutical Ingredients (APIs) with existing markets, including Willow's BioOxi -based corticosteroid processes, for large scale manufacturing, sales, and distribution at Laurus. Willow and Laurus expect these first programs to reach commercial manufacture in 2025.
Under the terms of the collaboration, Willow expects to earn significant annual revenues in research & development and royalties, including in guaranteed research & development payments in year one. Upon commercialization o.
